Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : KPG-818
Therapeutic Area : Immunology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Kangpu Completed Bridging Clinical Study of KPG-818 in China
Details : KPG-818 is a small molecule modulator of CRBN E3 ubiquitin ligase complex CRL4-CRBN. It is being evaluated for the treatment of Systemic Lupus Erythematosus.
Brand Name : KPG-818
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 20, 2024
Lead Product(s) : KPG-818
Therapeutic Area : Immunology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Lenalidomide Analog,Abiraterone Acetate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Precision Bio: PBGENE-HBV Preclinical Safety Data at EASL
Details : KPG-121 is a modulator of the CRL4CRBN complex targeting rapid ubiquitination and degradation of CK1 alpha, IKZF3 and IKZF1. It is being investigated in combination with Abiraterone for mCRPC.
Brand Name : KPG-121
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 05, 2024
Lead Product(s) : Lenalidomide Analog,Abiraterone Acetate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : KPG-818
Therapeutic Area : Immunology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Kangpu Completes Patient Enrollment for Phase IIa Clinical Trial of KPG-818 in SLE in the US
Details : KPG-818 is a novel generation of small molecule modulators of CRBN E3 ubiquitin ligase complex CRL4-CRBN. It provides a potent induction of the ubiquitination and degradation of Aiolos (IKZF3) and Ikaros (IKZF1), factors critical in B-cell development.
Brand Name : KPG-818
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 20, 2023
Lead Product(s) : KPG-818
Therapeutic Area : Immunology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : KPG-818
Therapeutic Area : Immunology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : KPG-818 is novel cereblon E3 ubiquitin ligase complex modulator for treatment of autoimmune diseases and hematologic malignancies, demonstrated good tolerability, a favorable pharmacokinetic profile, and substantial potency for the degradation of Ikaros ...
Brand Name : KPG-818
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 13, 2022
Lead Product(s) : KPG-818
Therapeutic Area : Immunology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : KPG-818
Therapeutic Area : Immunology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The Phase Ib/IIa multicenter, randomized, double-blind, placebo-controlled clinical study will evaluate the safety and tolerability, pharmacokinetics and preliminary efficacy of KPG-818 in patients with mild to moderate SLE.
Brand Name : KPG-818
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 16, 2020
Lead Product(s) : KPG-818
Therapeutic Area : Immunology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : KPG-121,Enzalutamide
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Two posters highlighting preclinical data of the company's lead drug candidates, KPG-121 and KPG-818, will be presented at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II.
Brand Name : KPG-121
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 17, 2020
Lead Product(s) : KPG-121,Enzalutamide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?